Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review.

ABSTRACT:

Context

Immune-checkpoint inhibitors (ICI) have shown significant benefits for overall survival across various cancer types. Patient-reported outcomes (PROs) are assessed in clinical trials as a measure of efficacy. However, it remains unclear to what extent current PRO instruments capture symptoms specific to ICI toxicities. We conducted a systematic review to identify the use and content validity of PRO instruments in ICI clinical trials in oncology.

Methods

Literature was retrieved from PubMed, Embase, PsycINFO, Medline and CINAHL databases. Articles presenting ICI clinical trials' PRO results, clinical trial study protocols, and conference abstracts stating the use of PRO measures were assessed. We evaluated the validity of identified instruments by comparing their sympt

SUBMITTER: Colomer-Lahiguera S 

PROVIDER: S-EPMC7364679 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature